Live Breaking News & Updates on Therapeutic Areas Communications

Stay updated with breaking news from Therapeutic areas communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Organization (ECCO) annual congress

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Organization (ECCO) annual congress
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Region Flamande , United Kingdom , Northern Ireland , Great Britain , Ailsa Hart , Stefan Schreiber , Edwardv Loftus Jr , Haridarshan Patel , James Oliver Lindsay , Anna Gibbins , Kristina Harris , Johan Michael Burisch , Van Gijsel , Sandra Cauwenberghs , Silvio Danese , Marieke Vermeersch , Severine Vermeire , Christine Rudolph , Michael Smyth , Javaria Mona Khalid , Hannah Knight , Rob Jongen , Alessandra Oortwijn , Bernd Bokemeyer , Patrick Daniele , Brian Feagan ,

Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Organization (ECCO) annual congress

Nine presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityFour new analyses from Phase 3 SELECTION and SELECTION long term extension studies of Jyseleca ....

Region Flamande , United Kingdom , Northern Ireland , Great Britain , Ailsa Hart , Stefan Schreiber , Edwardv Loftus Jr , Haridarshan Patel , James Oliver Lindsay , Anna Gibbins , Kristina Harris , Johan Michael Burisch , Van Gijsel , Sandra Cauwenberghs , Silvio Danese , Marieke Vermeersch , Severine Vermeire , Christine Rudolph , Michael Smyth , Javaria Mona Khalid , Hannah Knight , Rob Jongen , Alessandra Oortwijn , Bernd Bokemeyer , Patrick Daniele , Brian Feagan ,

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT

Mechelen, Belgium; 18 January 2022; 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products. ....

United Kingdom , Region Flamande , Northern Ireland , Great Britain , Van Gijsel , Sandra Cauwenberghs , Marieke Vermeersch , Anna Gibbins , Ian Beales , Michele Manto , Ruth Wakeman , Norwich University Hospital , European Commission , Gilead Sciences Inc , Therapeutic Areas Communications , Regulatory Agency , Japanese Ministry Of Health , European Union , Devices Agency , Japan Pharmaceuticals , Chief Commercial Officer , General Medicine , Chief Investigator , Colitis United Kingdom , Medical Devices Agency , Great Britain Summary ,

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Region Flamande , Northern Ireland , Great Britain , Anna Gibbinssenior , Ian Beales , Van Gijselsenior , Michele Manto , Ruth Wakeman , Norwich University Hospital , European Commission , Gilead Sciences Inc , Therapeutic Areas Communications , Regulatory Agency , Japanese Ministry Of Health , European Union , Devices Agency , Japan Pharmaceuticals , Chief Commercial Officer , General Medicine , Chief Investigator , Colitis United Kingdom , Medical Devices Agency , Great Britain Summary , Product Characteristics , Northern Ireland Summary ,

Investegate |Galapagos NV Announcements | Galapagos NV: JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

Investegate announcements from Galapagos NV, JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN ....

United Kingdom , Region Flamande , Northern Ireland , Great Britain , Van Gijsel , Sandra Cauwenberghs , Marieke Vermeersch , Anna Gibbins , Ian Beales , Michele Manto , Ruth Wakeman , Norwich University Hospital , European Commission , Gilead Sciences Inc , Therapeutic Areas Communications , Regulatory Agency , Japanese Ministry Of Health , European Union , Devices Agency , Japan Pharmaceuticals , Chief Commercial Officer , General Medicine , Chief Investigator , Colitis United Kingdom , Medical Devices Agency , Great Britain Summary ,